Equities research analysts expect that Luminex Co. (NASDAQ:LMNX) will report sales of $110.11 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Luminex’s earnings. The highest sales estimate is $112.64 million and the lowest is $105.30 million. Luminex posted sales of $90.42 million in the same quarter last year, which would indicate a positive year over year growth rate of 21.8%. The firm is expected to announce its next earnings report on Monday, May 3rd.
According to Zacks, analysts expect that Luminex will report full-year sales of $479.95 million for the current year, with estimates ranging from $479.53 million to $480.22 million. For the next fiscal year, analysts expect that the business will report sales of $532.65 million, with estimates ranging from $513.60 million to $562.05 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Luminex.
Luminex (NASDAQ:LMNX) last issued its earnings results on Sunday, February 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.12). Luminex had a return on equity of 3.75% and a net margin of 4.60%. The company had revenue of $111.39 million for the quarter, compared to the consensus estimate of $104.57 million. During the same quarter in the prior year, the company posted $0.07 EPS. Luminex’s revenue was up 23.1% compared to the same quarter last year.
LMNX stock traded up $0.67 during trading on Friday, hitting $32.95. 436,107 shares of the company’s stock traded hands, compared to its average volume of 633,048. Luminex has a 52 week low of $20.61 and a 52 week high of $41.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 5.01 and a current ratio of 6.45. The business has a fifty day simple moving average of $31.84 and a 200 day simple moving average of $26.53. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of 84.49 and a beta of 0.61.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 15th. Shareholders of record on Thursday, March 25th will be given a dividend of $0.10 per share. The ex-dividend date is Wednesday, March 24th. This represents a $0.40 annualized dividend and a yield of 1.21%. Luminex’s dividend payout ratio (DPR) is currently -190.48%.
In other Luminex news, CFO Harriss T. Currie sold 5,325 shares of the stock in a transaction on Monday, March 1st. The shares were sold at an average price of $32.35, for a total transaction of $172,263.75. 9.40% of the stock is owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Everence Capital Management Inc. bought a new stake in shares of Luminex in the 1st quarter worth about $302,000. Legacy Wealth Asset Management LLC bought a new stake in shares of Luminex in the 4th quarter worth about $361,000. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Luminex by 71.0% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 215,219 shares of the medical instruments supplier’s stock worth $4,973,000 after acquiring an additional 89,373 shares during the last quarter. Norges Bank bought a new stake in shares of Luminex in the 4th quarter worth about $14,662,000. Finally, UBS Asset Management Americas Inc. lifted its holdings in shares of Luminex by 16.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 44,597 shares of the medical instruments supplier’s stock worth $1,031,000 after acquiring an additional 6,376 shares during the last quarter. Hedge funds and other institutional investors own 88.09% of the company’s stock.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; FlowSight Imaging Flow cytometer; ImageStream System; CellStream Flow Cytometer; Guava easyCyte line; and Muse Cell Analyzer.
See Also: Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com